Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningokokal - cjepiva - nimenrix je indiciran za aktivnu imunizaciju osoba od dobi od 6 tjedana protiv invazivnih meningokoknih bolesti uzrokovanih neisseria meningitidis grupom a, c, w-135 i y.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokal - cjepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. sarajevo - meningokokus a, c, y, w135, četverovalentni prečišćeni polisaharidni antigen konjugovani - prašak i rastvarač za rastvor za injekciju u napunjenoj šprici - 5 µg/0.5 ml+ 5 µg/0.5 ml+ 5 µg/0.5 ml+ 5 µg/0.5 ml - 1 doza vakcine (0,5 ml) sadrži: 5 mcg neisseria meningitidis grupa a polisaharid 5 mcg neisseria meningitidis grupa c polisaharid 5 mcg neisseria meningitidis grupa w135 polisaharid 5 mcg neisseria meningitidis grupa y polisaharid

Europska Unija - hrvatski - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningokokna skupina a, c, w-135 i y konjugirano cjepivo - immunization; meningitis, meningococcal - bakterijska vakcina - vialsmenveo prikazana za aktivne imunizacije djece (od dvije godine), mladež i odrasle osobe sklone utjecaja na менингококк grupe a, c, w135 i y kako bi se spriječilo bolesti инвазионные. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis serotip b fhbp (rekombinantni lipidirani fhbp (protein koji veže faktor h)) podfamilija a; neisseria meningitidis serotip b fhbp (rekombinantni lipidirani fhbp (faktor vezanja h proteina)) podskupina b - meningitis, meningokokal - bacterial vaccines, meningococcal vaccines - trumenba je indicirana za aktivnu imunizaciju osoba starijih od 10 godina kako bi se spriječila invazivna meningokokna bolest uzrokovana neisseria meningitidis serotipom b. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

gsk vaccines s.r.l. - vanjska membrana везикулы od менингококк grupe b (soj 98/254 nc), рекомбинантный менингококк grupe u fhbp sintezu proteina, rekombinantnog менингококк grupe b nada protein, рекомбинантный менингококк grupe u nhba sintezu proteina - meningitis, meningokokal - meningokokna cjepiva - aktivna imunizacija protiv invazivnih bolesti uzrokovanih sojima neisseria meningitidis serogroup-b.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alexion europe sas - Экулизумаб - hemoglobinuria, paroxysmal - imunosupresivi - Солирис indiciran za odrasle i djecu, za liječenje:пароксизмальная noćni гемоглобинурия (apg). dokaza klinički učinak očituje se u bolesnika s гемолизом s klinički simptom(ova), ukazuje na visoke aktivnosti bolesti, bez obzira na priče transfuziju (vidi odjeljak 5. Атипичный гемолитико-уремический (agus). Солирис prikazan kod odraslih za liječenje:vatrostalne postati generalizirani миастенией gravis (ГГМ) u bolesnika s anti-ацетилхолиновому рецептору (АЧР) antitijela (vidi odjeljak 5. poremećaj neuromyelitis vidnog spektra (nmosd) kod pacijenata koji su anti-aquaporin-4 (aqp4) antitijela s recidivom tijekom bolesti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Europska Unija - hrvatski - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - Экулизумаб - hemoglobinuria, paroxysmal - imunosupresivi - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.